Modifiable pre-treatment factors are associated with quality of life in women with gynaecological cancers at diagnosis and one year later: Results from the HORIZONS UK national cohort study.


Journal

Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304

Informations de publication

Date de publication:
06 2022
Historique:
received: 20 09 2021
revised: 10 03 2022
accepted: 14 03 2022
pubmed: 31 3 2022
medline: 26 5 2022
entrez: 30 3 2022
Statut: ppublish

Résumé

Personalised care requires the identification of modifiable risk factors so that interventions can be implemented rapidly following a gynaecological cancer diagnosis. Our objective was to determine what pre-treatment factors are associated with quality of life (QOL) at baseline (pre-treatment) and 12 months. 1222 women with a confirmed diagnosis of endometrial, ovarian, cervical or vulvar cancer from 82 UK NHS hospitals agreed to complete questionnaires at baseline, three and 12 months. Questionnaires included measures of QOL, health, lifestyle, support and self-management. The primary outcome measure was QOL as measured by Quality of Life in Adult Cancer Survivors (QLACS). Sites provided clinical data at baseline, six and 12 months. Linear regression models were constructed to examine the association between baseline characteristics and QOL outcomes. QOL declined between baseline and 3 months, followed by an improvement at 12 months. Baseline (pre-treatment) factors associated with worse QOL at both baseline and 12 months were depression, anxiety, living in a more deprived area and comorbidities which limit daily activities, whereas higher self-efficacy and age of 50+ years were associated with better QOL. Depression, anxiety and self-efficacy are modifiable risk factors that can impact on QOL. Screening for these, and assessment of whether comorbidities limit daily activities, should be incorporated in a holistic needs assessment and interventions to improve self-efficacy should be made available. Care can then be personalised from the outset to enable all women with a gynaecological cancer the opportunity to have the best QOL.

Identifiants

pubmed: 35351333
pii: S0090-8258(22)00194-9
doi: 10.1016/j.ygyno.2022.03.012
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

610-618

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Rosalind Glasspool (R)

Beatson West of Scotland Cancer Centre and University of Glasgow, UK. Electronic address: ros.glasspool@ggc.scot.nhs.uk.

Sally Wheelwright (S)

Health Sciences, University of Southampton, UK.

Victoria Bolton (V)

Health Sciences, University of Southampton, UK.

Lynn Calman (L)

Health Sciences, University of Southampton, UK.

Amanda Cummings (A)

Health Sciences, University of Southampton, UK.

Beryl Elledge (B)

HORIZONS User Reference Group, University of Southampton, UK.

Rebecca Foster (R)

Health Sciences, University of Southampton, UK.

Jane Frankland (J)

Health Sciences, University of Southampton, UK.

Peter Smith (P)

Social Statistics and Demography, University of Southampton, UK.

Sebastian Stannard (S)

Social Statistics and Demography, University of Southampton, UK.

Joshua Turner (J)

Health Sciences, University of Southampton, UK.

David Wright (D)

Health Sciences, University of Southampton, UK.

Claire Foster (C)

Health Sciences, University of Southampton, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH